Secondary malignancies among nonseminomatous germ cell tumor cancer survivors

Cancer

Volumn 117, Issue 18, 2011, Pages 4219-4230

  Chamie, Karim ^a   Kurzrock, Eric A ^b   Evans, Christopher P ^b   Litwin, Mark S ^a   Koppie, Theresa M ^b   Wootton Gorges, Sandra L ^c   Boone, John M ^c   Lara Jr , Primo N ^b   Devere White, Ralph W ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

active surveillance; computed tomography; lymph node excision; neoplasms; retroperitoneal lymph node dissection; secondary; testis

Indexed keywords

ADULT; ARTICLE; CANCER INCIDENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVOR; CONTROLLED STUDY; GERM CELL TUMOR; HUMAN; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; NONSEMINOMATOUS GERM CELL TUMOR; PRIORITY JOURNAL; REGRESSION ANALYSIS; SCORING SYSTEM; SECOND CANCER; STATISTICAL MODEL;

ADOLESCENT; ADULT; HUMANS; LYMPH NODE EXCISION; MALE; MIDDLE AGED; NEOPLASMS, GERM CELL AND EMBRYONAL; NEOPLASMS, SECOND PRIMARY; RETROPERITONEAL SPACE; RISK; SURVIVORS; TESTICULAR NEOPLASMS;

EID: 80052486910     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26038     Document Type: Article

References (28)

1. Shahidi M, Norman AR, Dearnaley DP, Nicholls J, Horwich A, Huddart RA,. Late recurrence in 1263 men with testicular germ cell tumors. Multivariate analysis of risk factors and implications for management. Cancer. 2002; 95: 520-530. (Pubitemid 34810177)
2. Oldenburg J, Alfsen GC, Waehre H, Fossa SD,. Late recurrences of germ cell malignancies: a population-based experience over 3 decades. Br J Cancer. 2006; 94: 820-827.
3. Motzer RJ, Agarwal N, Beard C, et al. The NCCN Testicular Cancer Guidelines, version 1, 2008. Jenkintown, PA: National Comprehensive Cancer Network; 2008. Accessed December 9, 2007 2008.
4. Steele GS, Richie JP, Stewart AK, Menck HR,. The National Cancer Data Base report on patterns of care for testicular carcinoma, 1985-1996. Cancer. 1999; 86: 2171-2183.
5. Osswald M, Harlan LC, Penson D, Stevens JL, Clegg LX,. Treatment of a population based sample of men diagnosed with testicular cancer in the United States. Urol Oncol. 2009; 27: 604-610.
6. Koch MO,. Cost-effective strategies for the follow-up of patients with germ cell tumors. Urol Clin North Am. 1998; 25: 495-502. (Pubitemid 28384614)
7. Berrington de Gonzalez A, Mahesh M, et al. Projected cancer risks from computed tomographic scans performed in the United States in 2007. Arch Intern Med. 2009; 169: 2071-2077.
8. Smith-Bindman R, Lipson J, Marcus R, et al. Radiation dose associated with common computed tomography examinations and the associated lifetime attributable risk of cancer. Arch Intern Med. 2009; 169: 2078-2086.
9. Tarin TV, Sonn G, Shinghal R,. Estimating the risk of cancer associated with imaging related radiation during surveillance for stage I testicular cancer using computerized tomography. J Urol. 2009; 181: 627-632; discussion 632-633.
10. Pedersen-Bjergaard J, Daugaard G, Hansen SW, Philip P, Larsen SO, Rorth M,. Increased risk of myelodysplasia and leukaemia after etoposide, cisplatin, and bleomycin for germ-cell tumours. Lancet. 1991; 338: 359-363.
11. Redman JR, Vugrin D, Arlin ZA, et al. Leukemia following treatment of germ cell tumors in men. J Clin Oncol. 1984; 2: 1080-1087. (Pubitemid 14022693)
12. van den Belt-Dusebout AW, de Wit R, Gietema JA, Horenblas S, Louwman MW, Ribot JG, Hoekstra HJ, Ouwens GM, Aleman BM, van Leeuwen FE,. Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol. 2007; 25: 4370-4378. (Pubitemid 350013842)
13. National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) Program. Bethesda, MD: National Cancer Institute; 2010. Accessed August 21, 2010.
14. Kurth T, Walker AM, Glynn RJ, et al. Results of multivariable logistic regression, propensity matching, propensity adjustment, and propensity-based weighting under conditions of nonuniform effect. Am J Epidemiol. 2006; 163: 262-270. (Pubitemid 43145754)
15. Fine JP, Gray RJ,. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999; 94: 496-509.
16. May S, Hosmer DW,. Hosmer and Lemeshow type goodness-of-fit statistics for the Cox proportional hazards model. In:, Balakrishnana N, Rao CR, eds. Advances in Survival Analysis: Handbook of Statistics, Vol 23. Amsterdam, the Netherlands: Elsevier, North-Holland; 2004: 383-394.
17. Brenner DJ, Hall EJ,. Computed tomography-an increasing source of radiation exposure. N Engl J Med. 2007; 357: 2277-2284. (Pubitemid 350190758)
18. Brenner D, Elliston C, Hall E, Berdon W,. Estimated risks of radiation-induced fatal cancer from pediatric CT. AJR Am J Roentgenol. 2001; 176: 289-296. (Pubitemid 32105628)
19. Travis LB, Fossa SD, Schonfeld SJ, et al. Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst. 2005; 97: 1354-1365. (Pubitemid 41487803)
20. Preston DL, Ron E, Tokuoka S, et al. Solid cancer incidence in atomic bomb survivors: 1958-1998. Radiat Res. 2007; 168: 1-64. (Pubitemid 351292925)
21. Shuryak I, Sachs RK, Brenner DJ,. Cancer risks after radiation exposure in middle age. J Natl Cancer Inst. 2010; 102: 1628-1636.
22. Yu HY, Madison RA, Setodji CM, Saigal CS,. Quality of surveillance for stage I testis cancer in the community. J Clin Oncol. 2009; 27: 4327-4332.
23. Nichols CR, Kollmannsberger C,. Vox populi: using community-based studies to determine best management of early stage nonseminoma. J Clin Oncol. 2009; 27: 2114-2116.
24. Albers P,. Management of stage I testis cancer. Eur Urol. 2007; 51: 34-43, discussion 43-44.
25. Albers P, Siener R, Krege S, et al. Randomized phase III trial comparing retroperitoneal lymph node dissection with 1 course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO Trial AH 01/94 by the German Testicular Cancer Study Group. J Clin Oncol. 2008; 26: 2966-2972.
26. Stephenson AJ, Bosl GJ, Motzer RJ, et al. Retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer: impact of patient selection factors on outcome. J Clin Oncol. 2005; 23: 2781-2788. (Pubitemid 46179468)
27. Nicolai N, Piva L, Pizzocaro G, Salvioni R,. Re: Peter Albers. Management of stage I testis cancer: Eur Urol 2007;51:34-44. Eur Urol. 2007; 52: 295-296. (Pubitemid 46803024)
28. Rustin GJ, Mead GM, Stenning SP, et al. Randomized trial of 2 or 5 computed tomography scans in the surveillance of patients with stage I nonseminomatous germ cell tumors of the testis: Medical Research Council Trial TE08, ISRCTN56475197-the National Cancer Res. Institute Testis Cancer Clinical Studies Group. J Clin Oncol. 2007; 25: 1310-1315. (Pubitemid 46706876)